Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK228 plus weekly paclitaxel versus weekly paclitaxel in platinum-resistant ovarian-related cancers
2016-000065-23Phase 2Unknown
- Sponsor
- Imperial College London
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing TAK228 + weekly paclitaxel with Weekly paclitaxel (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
sapanisertibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2016-000065-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000065-23.